磺达肝癸钠,是一种新型抗血栓药物已继肝素及低分子肝素后由FDA批准适用于多种动静脉血栓症的**与预防。磺达肝癸钠属人工合成的特异性活化Xa因子抑制物,作用机制为通过选择性的与A皿n因子结合,使AITn中和已激活的Xa因子的作用增强约30倍,从而打断凝血瀑布反应起到抑制凝血酶生成及血栓进展的目的磺达肝癸钠对凝血酶无直接作用,但是通过抑制凝血因子Xa可以有效抑制凝血酶生成,据估计每抑制1分子Xa因子可阻止50分子凝血酶产生。
适应症: 磺达肝癸钠用于进行下肢重大骨科手术如髋关节骨折、重大膝关节手术或者髋关节置换术等患者,预防静脉血栓栓塞事件的发生。用于无指征进行紧急(<120分钟)侵入性**(PCI)的不稳定性心绞痛或非ST段抬高心肌梗死患者的**。用于使用溶栓或初始不接受其它形式再灌注**的ST段抬高心肌梗死患者的**。
磺达肝癸钠CAS号:114870-03-0
磺达肝癸钠分子式: C31H43N3Na10O49S8
磺达肝癸钠英文名称: Fondaparinux sodium
磺达肝癸钠英文同义词: decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-carboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-carboxylate; decasodium (2R,3S,4S,5R,6R)-3-({(2R,3R,4R,5R,6R)-5-{[(2R,3R,4R,5S,6S)-6-carboxylato-5-({(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-[(sulfonatooxy)methyl]tetrahydro-2H-pyran-2-yl}oxy)-3,4-dihydroxytetrahydro-2H-pyran-2-yl]oxy}-3-(sulfonatoamino)-4-(sulfonatooxy)-6-[(sulfonatooxy)methyl]tetrahydro-2H-pyran-2-yl}oxy)-4-hydroxy-6-({(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-[(sulfonatooxy)methyl]tetrahydro-2H-pyran-3-yl}oxy)-5-(sulfonatooxy)tetrahydro-2H-pyran-2-carboxylate (non-preferred name)
磺达肝癸钠分子量: 1728.0815